T细胞受体
免疫疗法
抗原
过继性细胞移植
癌症免疫疗法
免疫学
癌症
肿瘤浸润淋巴细胞
癌症研究
黑色素瘤
医学
T细胞
免疫系统
内科学
作者
Florian Bieberich,Sai T. Reddy
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2023-09-05
卷期号:83 (19): 3168-3169
被引量:1
标识
DOI:10.1158/0008-5472.can-23-2594
摘要
Abstract The ability of T-cell receptors (TCR) to recognize tumor-associated antigens (TAA) is a key driver of adoptive transfer of tumor-infiltrating lymphocyte (TIL) T cells, which can be a highly effective cancer immunotherapy. While it is common knowledge that TCRs are cross-reactive and can bind multiple different peptide antigens, this is typically considered an unattractive feature and limitation for TCR-based therapies. In a recent publication in Cell, Dolton and colleagues discover that certain TCRs, isolated from TILs used for successful treatment of melanoma, possess beneficial cross-reactivity by recognizing multiple TAA. Moreover, they elucidate the cumulative value of TCR cross-reactivity on cancer cell eradication and its prospective advantages for targeted cancer immunotherapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI